VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+11.92%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$191M
AUM Growth
-$59.3M
(-24%)
Cap. Flow
-$77.9M
Cap. Flow
% of AUM
-40.7%
Top 10 Holdings %
Top 10 Hldgs %
5.8%
Holding
489
New
53
Increased
164
Reduced
226
Closed
46
Top Buys
| 1 |
D.R. Horton
DHI
|
$987K |
| 2 |
Lennar Class A
LEN
|
$952K |
| 3 |
Freeport-McMoran
FCX
|
$917K |
| 4 |
TJX Companies
TJX
|
$909K |
| 5 |
Ametek
AME
|
$905K |
Top Sells
| 1 |
Steel Dynamics
STLD
|
$1.65M |
| 2 |
NOA
North American Construction
NOA
|
$1.55M |
| 3 |
Alamos Gold
AGI
|
$1.53M |
| 4 |
Cheniere Energy
CQP
|
$1.51M |
| 5 |
GTY
Getty Realty Corp
GTY
|
$1.5M |
Sector Composition
| 1 | Healthcare | 26.88% |
| 2 | Financials | 12.6% |
| 3 | Technology | 10.15% |
| 4 | Materials | 9.55% |
| 5 | Real Estate | 8.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
251
Vanda Pharmaceuticals
VNDA
$272M
| $309K | 0.16% |
41,789
+16,855
| +68% | +$125K |
|
252
Ultragenyx Pharmaceutical
RARE
$3.07B
| $308K | 0.16% |
6,655
+1,690
| +34% | +$78.3K |
|
253
BlackRock Debt Strategies Fund
DSU
$547M
| $307K | 0.16% |
33,421
-6,979
| -17% | -$64.2K |
|
254
Alnylam Pharmaceuticals
ALNY
$59.2B
| $307K | 0.16% |
1,293
-468
| -27% | -$111K |
|
255
Amylyx Pharmaceuticals
AMLX
$910M
| $307K | 0.16% |
+8,307
| New | +$307K |
|
|
BSL
256
Blackstone Senior Floating Rate 2027 Term Fund
BSL
$186M
| $306K | 0.16% |
24,630
-2,052
| -8% | -$25.5K |
|
257
Acadia Pharmaceuticals
ACAD
$4.26B
| $305K | 0.16% |
19,173
+4,680
| +32% | +$74.5K |
|
258
Ascendis Pharma
ASND
$12.5B
| $304K | 0.16% |
2,491
-409
| -14% | -$50K |
|
259
United Therapeutics
UTHR
$18.1B
| $304K | 0.16% |
1,093
+16
| +1% | +$4.45K |
|
|
ITCI
260
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $303K | 0.16% |
5,733
+1,376
| +32% | +$72.8K |
|
|
MYOV
261
DELISTED
Myovant Sciences Ltd.
MYOV
| $303K | 0.16% |
11,251
-11,439
| -50% | -$308K |
|
262
Neurocrine Biosciences
NBIX
$14.3B
| $303K | 0.16% |
2,537
-45
| -2% | -$5.38K |
|
263
Theravance Biopharma
TBPH
$703M
| $303K | 0.16% |
26,989
-520
| -2% | -$5.83K |
|
264
Insmed
INSM
$30.7B
| $302K | 0.16% |
15,135
+1,594
| +12% | +$31.8K |
|
265
Ironwood Pharmaceuticals
IRWD
$188M
| $302K | 0.16% |
24,399
+3,829
| +19% | +$47.4K |
|
266
Barings BDC
BBDC
$987M
| $302K | 0.16% |
36,998
-230
| -0.6% | -$1.88K |
|
267
Exelixis
EXEL
$10.2B
| $300K | 0.16% |
18,688
+5,361
| +40% | +$86K |
|
268
Ionis Pharmaceuticals
IONS
$9.76B
| $298K | 0.16% |
7,900
+871
| +12% | +$32.9K |
|
269
Rhythm Pharmaceuticals
RYTM
$6.78B
| $298K | 0.16% |
+10,221
| New | +$298K |
|
270
Apellis Pharmaceuticals
APLS
$3.55B
| $297K | 0.16% |
5,743
-313
| -5% | -$16.2K |
|
271
Amicus Therapeutics
FOLD
$2.46B
| $297K | 0.15% |
24,301
-5,397
| -18% | -$65.9K |
|
|
EFR
272
Eaton Vance Senior Floating-Rate Fund
EFR
$343M
| $296K | 0.15% |
27,087
-3,061
| -10% | -$33.5K |
|
|
DCF
273
DELISTED
BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc.
DCF
| $295K | 0.15% |
41,751
-13,604
| -25% | -$96K |
|
|
SGEN
274
DELISTED
Seagen Inc. Common Stock
SGEN
| $294K | 0.15% |
2,291
+661
| +41% | +$84.9K |
|
275
Halozyme
HALO
$8.76B
| $294K | 0.15% |
5,170
-230
| -4% | -$13.1K |
|